Context: Yellow phosphorus (YP) 3% is one of the rodenticides available, which is a potent hepatotoxin and it is fatal. Management of YP poisoning is difficult since there is no antidote available; only definitive management is liver transplantation. Therapeutic plasma exchange (TPE) helps the YP poisoning patients by removing the poison or its metabolite or the inflammatory mediators released in the body in response to toxin.
Aims: To determine the role of TPE in rat killer (YP) poisoning.
Settings And Design: This was a descriptive period study conducted from November 2018 to September 2020.
Subjects And Methods: Sixteen consecutive YP poisoning patients were included in the study ( = 16). A total of 48 sessions of TPE were carried out. Liver function tests such as serum glutamic-oxaloacetic transaminase, SGPT, total bilirubin, and direct bilirubin as well as coagulation profile such as prothrombin time, activated partial thromboplastin time, and international normalized ratio were analyzed at the time of admission, after each TPE session, and at the time of discharge.
Statistical Analysis Used: The results were recorded, and it was analyzed statistically by SPSS version 17.
Results: Liver function tests improved significantly from the time of admission and after each TPE and at the time of discharge ( < 0.05). Coagulation profile improved statistically ( < 0.05). Thirteen patients were improved in their clinical status, and three patients left the hospital citing personal reasons.
Conclusions: TPE could potentially bridge the gap between medical management and liver transplantation in cases of YP poisoning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180793 | PMC |
http://dx.doi.org/10.4103/ajts.ajts_20_21 | DOI Listing |
Arq Bras Cir Dig
January 2025
Universidade de São Paulo, Faculty of Medicine, Department of Gastroenterology - São Paulo (SP), Brazil.
Background: Obesity is a predisposing factor for serious comorbidities, particularly those related to elevated cardiovascular mortality. The atherogenic index of plasma (AIP) has been shown to be a useful indicator of patients with insulin resistance.
Aims: The aim of this study was to assess cardiovascular risk before and after surgical treatment of obesity.
Int Urol Nephrol
January 2025
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Purpose: Urinary cytokine changes may serve as biomarkers to assess treatment outcomes for interstitial cystitis/bladder pain syndrome (IC/BPS). This study analyzed the changes in urinary cytokines following various bladder therapies and explored their clinical significance in therapeutic mechanisms.
Methods: A total of 122 patients with IC/BPS treated with platelet-rich plasma (PRP), botulinum toxin-A (BoTN-A), hyaluronic acid (HA), or low-energy shock wave (LESW) were evaluated.
Target Oncol
January 2025
Berenson Cancer Center, West Hollywood, CA, USA.
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with this disease. Key developments include the use of chemotherapy, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
View Article and Find Full Text PDFAnesthesiology
January 2025
Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background: Tranexamic acid is an anti-fibrinolytic agent routinely used during hip and knee joint replacement surgery to minimize bleeding. Chronic kidney disease is a common chronic health problem seen among adults requiring major arthroplasty surgery. Tranexamic acid is renally cleared and may accumulate in chronic kidney disease.
View Article and Find Full Text PDFJACC Adv
February 2025
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.
Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.
Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!